Navelbine (Vinorelbine Tartrate)

Vinorelbine, the active ingredient in Navelbine, is a Vinca alkaloid presented as an injectable solution for intravenous use. It treats certain types of cancer, specifically non‑small cell lung cancer and breast cancer, in adult patients. GNH USA supplies Navelbine as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Vinorelbine is used in the treatment of solid tumours, particularly those that are responsive to antimitotic therapy. - Non‑small cell lung cancer: used as first‑line or second‑line therapy to control tumour growth. - Breast cancer: employed in metastatic settings, often combined with other agents to delay progression. - Solid tumours in combination regimens: incorporated with other chemotherapeutics to enhance antitumour activity in various advanced cancers.

Vinorelbine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: reduced white blood cell count increasing infection risk. - Constipation: difficulty passing stools.

Serious or Rare Side Effects: - Severe neutropenia with fever: potentially life‑threatening infection. - Thrombocytopenia: low platelet count leading to bleeding. - Pulmonary toxicity: interstitial pneumonitis or fibrosis.

When using Navelbine, several precautions should be observed. - Monitor blood counts: regular CBC to detect neutropenia or anemia. - Assess liver function: adjust therapy if hepatic impairment is present. - Evaluate cardiac status: baseline ECG recommended due to potential arrhythmias. - Avoid concurrent myelosuppressive agents: reduces risk of severe bone‑marrow suppression. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with specialist. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinorelbine interacts with several drug classes and should be managed accordingly.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase vinorelbine exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Concurrent myelosuppressive chemotherapy: heightens risk of severe neutropenia.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): increased bleeding risk due to thrombocytopenia. - Radiotherapy: may exacerbate bone‑marrow suppression. - P‑glycoprotein substrates (e.g., digoxin): potential alteration in plasma levels.